Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-09

Study Completion Date

2023-01-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is Double-Blind, Placebo-Controlled Multicentre Clinical Phase III Study conducted in 10 medical facilities. The objective of the study is to evaluate efficacy and safety of the drug Drug RADAMIN®VIRO, Lyophilisate for Preparation of Solution for Intramuscular and Subcutaneous Administration for COVID-19 Postexposure Prophylaxis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

NCT04847544

Covid19

COMPLETED PHASE2

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

NCT04343651

Coronavirus Disease 2019

COMPLETED PHASE2

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

NCT04464460

Coronavirus Disease

WITHDRAWN PHASE1

A Trial of Remdesivir in Adults With Severe COVID-19

NCT04257656

COVID-19 Remdesivir SARS-CoV-2

TERMINATED PHASE3

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

NCT04292899

COVID-19

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Upon signing the informed consent form and screening, 800 eligible subjects resides with a person with confirmed COVID-19 were randomized at a 1:1 ratio to receive either RADAMIN®VIRO once intramuscularly 5 mg (1 vial) or 1 vial of placebo once intramuscularly

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Double-stranded RNA sodium salt

Arm 1 (n=400) received the study drug RADAMIN®VIRO once intramuscularly, 5 mg (1 vial).

Group Type EXPERIMENTAL

Double-Stranded RNA sodium salt

Intervention Type DRUG

Once intramuscular injection 5 mg (1 vial)

Placebo

Arm 2 (n = 400) received 1 vial of placebo once intramuscularly

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Once intramuscular injection (1 vial)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Double-Stranded RNA sodium salt

Once intramuscular injection 5 mg (1 vial)

Intervention Type DRUG

Placebo

Once intramuscular injection (1 vial)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RADAMIN®VIRO

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects aged 18 to 80 inclusive (subjects) as of the time of signing the Subject Information Sheet (SIS) Informed Consent Form.
2. A subject resides with a person with confirmed COVID-19 who meets both of the following criteria:

* The first positive result for SARS-CoV-2 RNA laboratory test with nucleic acid amplification techniques (NAAT) or SARS-CoV-2 antigen with immunochromatographic assay, obtained up to 72 hours prior to randomisation of a subject participating in the study.
* At least one of the symptoms typical of COVID-19 is observed, with symptoms onset no more than 5 days prior to the randomisation of the subject participating in the study.
3. Negative result for antigen of SARS-CoV-2 with immunochromatographic assay.
4. No symptoms typical of COVID-19 observed.
5. A subject is expected to continue to reside with a person with confirmed COVID-19 during the entire clinical study period; hospitalisation of a person with officially confirmed COVID-19 is not needed at the time of study subject's randomisation.
6. Subject's consent to use reliable contraception methods during the entire study and for 3 weeks after the end of the study. Reliable contraception methods are: sexual abstinence, the use of a condom combined with a spermicidal agent. Female subjects incapable of bearing children (history: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as male subjects with infertility or a history of vasectomy may participate in the study.
7. Availability of SIS Informed Consent Form signed and dated by a patient.
8. Availability of Informed Consent Form for collection of information on COVID-19 signed and dated by a person with confirmed COVID-19.

Exclusion Criteria

1. Hypersensitivity to the study drug components, procaine.
2. Contraindications to intramuscular injections.
3. Contact with 2 or more persons with confirmed COVID-19 within a month prior to screening or residing with 2 or more people with officially confirmed COVID-19 at the time of screening.
4. Joint residence with more than 10 people.
5. Laboratory-confirmed case of COVID-19 within 6 months prior to randomisation.
6. Vaccination against COVID-19 within less than 4 weeks prior to screening.
7. Use or necessity to use unauthorised pharmaceuticals at the time of screening.
8. Use of immunostimulatory, immunomodulatory, or immunosuppressive medications within 3 months prior to screening.
9. Subjects undergoing renal replacement therapy or with a history of severe renal insufficiency (estimated glomerular filtration rate (GFR) \< 30 ml/min/1.73 m2, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, within 6 months prior to screening).
10. Primary biliary cirrhosis class C according to the Child - Pugh classification or a history of chronic or active hepatitis B or C.
11. Positive test result for HIV, syphilis, hepatitis B and/or C at the time of screening.
12. Chronic cardiac failure, Functional Class 3 III-IV according to the New York Heart Association (NYHA) Functional Classification.
13. A history of malignant tumours, except for subjects with disease being not observed within the last 5 years, subjects with completely cured basal cell skin cancer, or completely cured carcinoma in situ.
14. Alcohol, pharmacological and/or drug dependence (history and/or at the time of screening).
15. Schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorder (history or suspected) at the time of screening.
16. Any history data that may complicate, in the opinion of the investigator, interpretation of the study results or create additional risk for the subject due to his/her participation in the study.
17. Unwillingness or inability of a subject to comply with the Protocol procedures (in the opinion of the investigator).
18. Pregnant or lactating women, or women planning a pregnancy.
19. Participation in another clinical study within 3 months prior to enrolment in the present study.
20. Other conditions that prevent the subject from inclusion in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No